Hansoh Pharmaceutical Group Company Limited
3692
Classificação em ações
#947
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Preço da ação
$4.20
Valor de mercado
$25.49B
Variação (1 dia)
3.53%
Variação (1 ano)
-10.34%
País
CN
Negociar Hansoh Pharmaceutical Group Company Limited (3692)
Categoria
Healthcare
EPS de Hansoh Pharmaceutical Group Company Limited (3692)
EPS em June 2026 TTM: $0.16
De acordo com os últimos relatórios financeiros e o preço das ações da Hansoh Pharmaceutical Group Company Limited, o EPS atual da empresa (TTM) é $0.16. No final de 2023, a empresa teve um EPS de $0.07, um aumento em relação a ao EPS de 2022, que foi de $0.06.
Histórico de EPS da Hansoh Pharmaceutical Group Company Limited de 2016 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| 2026 (TTM) | $0.16 | 59.40% |
| 2024 | $0.10 | 43.63% |
| 2023 | $0.07 | 10.66% |
| 2022 | $0.06 | -11.88% |
| 2021 | $0.07 | 7.42% |
| 2020 | $0.07 | -0.15% |
| 2019 | $0.07 | 40.63% |
| 2018 | $0.05 | 11.63% |
| 2017 | $0.04 | 14.97% |
| 2016 | $0.04 | 0.00% |
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | 249.00% |
IN
|
